Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRx0237 in behavioral variant frontotemporal dementia
NCT01626378Phase 3Completed
- Sponsor
- TauRx Therapeutics Ltd
- Start
- May 2013
- Primary completion
- Feb 2016
- Countries
- 12
01
Overview
Phase 3, randomised, double-blind trial of hydromethylthionine mesylate in frontotemporal dementia (FTD), sponsored by TauRx Therapeutics Ltd. Started May 2013; status: completed.
02
Drugs
hydromethylthionine mesylate
03
Conditions
frontotemporal dementia (FTD)
Beyond the preview
Go deeper on NCT01626378.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01626378.